Schedule 13G ownership disclosure

Maze Therapeutics Inc

Common Stock, par value $0.001 per share · CUSIP: 578784100

Event date: 2025-03-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • GV 2019, L.P.

    Shares: 1,807,907.00 · Class: 4.1%

  • GV 2019 GP, L.P.

    Shares: 1,807,907.00 · Class: 4.1%

  • GV 2019 GP, L.L.C.

    Shares: 1,807,907.00 · Class: 4.1%

  • GV 2023, L.P.

    Shares: 604,564.00 · Class: 1.4%

  • GV 2023 GP, L.P.

    Shares: 604,564.00 · Class: 1.4%

  • GV 2023 GP, L.L.C.

    Shares: 604,564.00 · Class: 1.4%

  • Alphabet Holdings LLC

    Shares: 2,412,471.00 · Class: 5.5%

  • XXVI Holdings Inc.

    Shares: 2,412,471.00 · Class: 5.5%

  • Alphabet Inc.

    Shares: 2,412,471.00 · Class: 5.5%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001415889-25-012489
Form type
SCHEDULE 13G
Filer
GV 2019, L.P.
CIK
CIK 1845041
Filed
May 09, 2025
Reporting period
Mar 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub